StreetAlpha.app
Home › Stocks › RNXT

RenovoRx, Inc. (RNXT)

$1.04
▲ +11.23%
LAST CLOSE · NOV 17

RenovoRx develops RenovoCath, a drug delivery device, and other drug and device combination products for healthcare providers. It last closed at $1.04 on Nov 17, up 11.23% on the day.

AI Auto Pilots
Is RNXT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$2.8M
Net income
−$13.0M
−469.0% margin
EPS (diluted)
−$0.31
Free cash flow
−$12.2M
−440.4% margin
Valuation
Market cap
$50.2M
48.3M shares
P/E
–
No P/E while losing money
Price to sales
18.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$10.4M
At Sep 30
Shareholder equity
$9.3M
Shares outstanding
48.3M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $43K$43KFY2024FY2025: $1.1M$1.1MFY2025

From RNXT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated RNXT in the past 90 days, not enough for a consensus
Average 12-month target
$15.00
▲ 1342.3% upside

Based on 1 analyst who set a price target on RNXT in the past 90 days. The average target is $15.00, with a high of $15.00 and a low of $15.00, compared with the last close of $1.04.

Low $15.00Avg $15.00High $15.00
Blue marker: last close $1.04
Highest target$15.00
Average target$15.00
Lowest target$15.00
Latest rating changes
Ascendiant CapitalTarget raised
Nov 9Buy$14.50 → $15
Ascendiant CapitalTarget raised
Aug 28Buy$14 → $14.50
Ascendiant CapitalMaintained
Jun 1Buy$14
DateFirmActionRatingPrice target
Nov 9Ascendiant CapitalTarget raisedBuy$14.50 → $15
Aug 28Ascendiant CapitalTarget raisedBuy$14 → $14.50
Jun 1Ascendiant CapitalMaintainedBuy$14
Loading…

Technical Analysis

RNXT · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 19% below its 20 day and 34% below its 50 day average. It is 7% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 39). The nearest support is the Pivot at $1.02, and the nearest resistance the Pivot R1 at $1.07.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 13.7%/day
Key levels
$2.5952 week high+149.0%
$1.4050 day average+34.6%
$1.30100 day average+25.0%
$1.2320 day average+18.3%
$1.20Swing high (Aug 7)+15.4%
$1.11200 day average+6.7%
$1.07Pivot R1+2.9%
$1.04Last close
$1.02Pivot−1.9%
$0.98Pivot S1−5.8%
$0.88Swing low (Nov 6)−15.4%
$0.7352 week low−29.8%
Indicators
RSI (14)38.55Weak, oversold below 30Neutral
MACD-0.09Below its signal lineBearish
Stochastic18.7Near the bottom of its rangeOversold
ADX (14)16.6No clear trend
Williams %R-76.1Oversold below −80, overbought above −20Neutral
CCI (20)-141.9Oversold below −100, overbought above 100Oversold
Rate of change−19.4%Change over 10 sessionsBearish
ATR (14)$0.14Typical daily range, 13.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNXT

What happened before

See how RNXT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow RNXT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How RNXT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in RNXT in the last 90 days.

Loading…

See today’s whale options flow across the market →

RNXT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲27 buying vs 7 selling
  • ▲Held by funds +6.4 pts
  • ▲Funds holding +12
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4028+42.9%
In funds' top 1000–
Held by funds25.4%19.1%+6.4 pts
New / increased15 / 123 / 8+145.5%
Reduced / sold out3 / 46 / 6−41.7%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNXT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNXT is in one of them and how their past RNXT trades turned out.

RNXT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNXT in an article yet. Here's the latest on the wider market.

About RenovoRx

RenovoRx is a medical device company based in Mountain View, California. It develops RenovoCath, a proprietary drug delivery device sold as a standalone product, along with other products that combine drugs and devices. Its product candidates are still in clinical trials. Its customers are expected to include physicians, hospitals and other healthcare providers, whose care may be paid for by government programs and private insurers.

Headquarters
Mountain View, CA